COVID-19 Vaccine Boosters in Patients With CKD
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 273 participants.
Also called NCT05022329
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 273 participants
- Sponsor
- Registry
-
NCT05022329
-
- Main results
- BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada
- Registry status
- Terminated
Technical summary
Registry record NCT05022329. Randomized; triple masking; primary purpose prevention. Start 2021-09-30 (actual); primary completion 2022-05-11 (actual). Results posted on 2025-02-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COVID-19 Vaccine Boosters in Patients With CKD
- Acronym
- BOOST KIDNEY
- Condition
- Chronic Kidney Diseases
- Condition
- COVID-19
- Intervention (Biological)
- Pfizer-BioNTech COVID-19 Vaccine
- Intervention (Biological)
- MODERNA SARS-CoV-2 Vaccine
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Collaborator
- University Health Network, Toronto
- Collaborator
- Unity Health Toronto
- Collaborator
- Scarborough General Hospital
- Collaborator
- Providence Healthcare
Record details
- Record id
cardio:ct-nct05022329- Content hash
47629be5f1770f1530b5b05f2ee08026d5ad2794bb7f035210ffe95a26550ec0